We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A four-drug combination therapy has shown significant benefit for patients with newly diagnosed myeloma, according to a new analysis led by researchers from The Institute of Cancer Research, London (ICR).